Detalles de la búsqueda
1.
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry.
J Am Acad Dermatol;
90(1): 82-90, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37739267
2.
Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
Clin Exp Rheumatol;
35(5): 791-798, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28339358
3.
Life-threatening dermatologic adverse events in oncology.
Anticancer Drugs;
25(2): 225-34, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24108082
4.
Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach.
Front Med Technol;
6: 1200400, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38591045
5.
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry.
J Dermatolog Treat;
35(1): 2287401, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38073528
6.
Use of number needed to treat in cost-effectiveness analyses.
Ann Pharmacother;
47(3): 380-7, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23463742
7.
Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States.
J Dermatolog Treat;
34(1): 2200870, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154473
8.
Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States.
J Dermatolog Treat;
34(1): 2200869, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37025014
9.
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
Rheumatol Ther;
8(1): 167-181, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33244703
10.
Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis.
Adv Ther;
38(10): 5302-5316, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34515976
11.
Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study.
Adv Ther;
36(7): 1672-1683, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31102202
12.
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.
Adv Ther;
36(8): 1851-1877, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31168766
13.
Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis.
J Comp Eff Res;
7(10): 959-974, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30129776
14.
Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study.
Adv Ther;
35(5): 655-665, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29748914
15.
Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial.
Rheumatol Ther;
5(1): 123-134, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29574622
16.
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Clin Ther;
39(8): 1618-1627, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28729087
17.
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.
Rheumatol Ther;
4(2): 375-389, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28840531
18.
Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.
Clinicoecon Outcomes Res;
9: 451-458, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28814890
19.
Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.
Clin Ther;
39(8): 1600-1617, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28716293
20.
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study.
Rheumatol Ther;
4(1): 85-96, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28361468